Archives
-
L1023 Anti-Cancer Compound Library for Oncology
2026-09-11
The L1023 Anti-Cancer Compound Library combines 1164 pre-dissolved bioactive compounds for cancer research and high-throughput screening. Its target diversity includes a BRAF kinase inhibitor class, mTOR-directed agents, proteasome inhibitors, deubiquitinase inhibitors, and HDAC inhibitors, while the cited STING study supplies a mechanistic framework for immune-oncology screening.
-
HRP Goat Anti-Mouse IgG (H+L) Antibody Guide
2026-09-11
HRP Goat Anti-Mouse IgG (H+L) Antibody is an affinity-purified, HRP-conjugated secondary reagent for detecting mouse IgG primary antibodies in Western blotting, ELISA, IHC, and ICC. It should not be used as a universal secondary for non-mouse or non-IgG primaries, and assay-specific dilution and incubation conditions require laboratory validation.
-
Bile Acid Retention Drives Immune Escape in MASH-HCC
2026-09-10
A 2026 Cancer Letters study identifies a GPR120–FXR/ABCB11–bile acid–NLRC5 pathway that suppresses MHC-I antigen presentation in MASH-associated hepatocellular carcinoma. Its genetic and pharmacological experiments show that reducing intracellular bile acid retention can restore tumor antigenicity and improve anti-PD-1 responses in mice.
-
TMEM16F in Kupffer Cells Protects Against Listeria
2026-09-10
This study identifies Kupffer-cell TMEM16F, rather than TMEM16F in T or B cells, as a key determinant of liver protection during Listeria monocytogenes infection. Its findings connect plasma-membrane repair and lipid scrambling with control of hepatic inflammation, tissue injury, and metabolic disruption, providing a cell-specific framework for studying infection-associated inflammatory cell death.
-
Aclacinomycin A: From DNA Damage to rDNA Stress
2026-09-09
Aclacinomycin A research extends beyond general cytotoxicity to reveal how topological stress, persistent DNA lesions, and nucleolar compartmentalization can shape assay interpretation. This article connects aclarubicin pharmacology with rDNA damage biology while defining practical controls for apoptosis and DNA damage studies.
-
Tp47 Drives Macrophage Inflammatory Senescence
2026-09-09
The reference study identifies a mechanistic link between the Treponema pallidum protein Tp47, PKM2-dependent metabolic reprogramming, and inflammatory senescence in macrophages. Its findings suggest that pathogen-driven glycolysis, lactate production, EIF2AK2 signaling, and NLRP3-associated pyroptosis should be evaluated together when interpreting senescent cell detection in infection models.
-
Imatinib Hydrochloride: Mechanism and Research Use
2026-09-08
Imatinib hydrochloride, also called STI571 hydrochloride, is an ATP-site tyrosine kinase inhibitor for cancer research that targets v-Abl, c-Kit, and PDGFR. Its reported biochemical potency and research applications support chronic myelogenous leukemia and gastrointestinal stromal tumor models, while assay-specific cellular potency must be interpreted separately.
-
HyperFluor 488: A Decision Framework
2026-09-08
HyperFluor 488 Goat Anti-Human IgG (H+L) Antibody supports sensitive fluorescent detection of human IgG across translational immunoassays. This article explains when it is scientifically appropriate for vaccine research, how to avoid species-mismatch errors, and how to connect binding-antibody data with preclinical findings.
-
Western Secondary Antibody Dilution Buffer Guide
2026-09-07
This scenario-driven guide explains how Western Secondary Antibody Dilution Buffer, SKU K4115, can improve the consistency of protein-detection Western blots used alongside cell viability, proliferation, and cytotoxicity assays. It covers compatibility, reuse, optimization, data interpretation, and practical product-selection criteria.
-
RPS6 as a Translational Readout in PDAC
2026-09-07
RPS6 can serve as a practical bridge between membrane signaling, ribosome biogenesis, and proliferative output in pancreatic ductal adenocarcinoma. This article explains how to position an Anti-RPS6 antibody within mechanistic studies of the LRRC8A–Caveolin-1 axis, how to select orthogonal assays, and where an RPS6 monoclonal antibody adds value without overstating what total-protein measurements can prove.
-
Pam3CSK4: TLR1/2 Agonist for Inflammation Research
2026-09-05
Pam3CSK4 is a synthetic TLR1/2 agonist for controlled innate immune stimulation and inflammation research. It supports studies of immune cell activation, macrophage nitric oxide production, allergic airway inflammation models, and context-dependent neuroimmune regulation.
-
EPZ-6438: Selective EZH2 Inhibitor
2026-09-04
EPZ-6438 is a potent EZH2 inhibitor that targets the SAM-binding pocket and suppresses H3K27me3 formation. Product data support its use in epigenetic cancer research, including SMARCB1-deficient malignant rhabdoid tumor models and EZH2-mutant lymphoma xenografts.
-
Carfilzomib (PR-171) Workflow for Cancer Research
2026-09-04
Carfilzomib (PR-171) converts proteasome-mediated proteolysis inhibition into a practical platform for studying protein stress, apoptosis, paraptosis, and ferroptosis. This workflow translates recent ESCC radiosensitization findings into controlled dose-finding, combination-treatment, and troubleshooting strategies for cancer research.
-
Recombinant Mouse IFN-γ in MASH-HCC Assays
2026-09-03
Recombinant Mouse IFN-γ provides a defined functional challenge for testing whether bile acid-stressed MASH-HCC cells can recover antigen presentation. This workflow separates cytokine-response competence from defects in the GPR120–bile acid–NLRC5 axis while supporting antiviral, macrophage, and broader immunomodulatory assay development.
-
HyperFluor 488 Goat Anti-Mouse IgG Workflow
2026-09-03
Build sensitive, reproducible immunofluorescence, flow cytometry, and western blot workflows around a fluorescently labeled secondary antibody. This practical guide translates hyperoxia-driven DRP1 and glycolysis findings in ATII cells into assay design, signal-amplification choices, and troubleshooting steps.